MOSCOW (MRC) -- AGC has begun evaluating an expansion of production capacity at its chlor-alkali subsidiary, Vinythai, as part of its initiative to expand its chlor-alkali business in Thailand, as per Apic-online.
The project would involve increasing the production capacity of polyvinyl chloride to 860,000 t/y from 300,000 t/y, vinyl chloride monomer to 830,000 t/y from 400,000 t/y and caustic soda to 590,000 t/y from 370,000 t/y. A final decision will be made based on the findings of the environmental and health impact assessments.
AGC, which acquired Vinythai in 2017, is currently undertaking measures toward integrating Vinythai with the nearby AGC Chemicals (Thailand) Co. to increase the synergy of the two companies.
The company has plans to install a pipeline between the two businesses to share chlorine production.
As MRC wrote before, in December 2016, CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins and AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announced that they had entered into a definitive agreement with CMC Biologics' shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC will acquire 100% of CMC Biologics' shares.
Asahi Glass Co., Ltd., more commonly known as AGC, is a global glass manufacturing company, headquartered in Tokyo. It is one of the core Mitsubishi companies.
MRC